A Success Story at a Glance

Within only a few years since its foundation in 2003, CEVEC has established a growing global customer base in the major biopharmaceutical markets.

  • 2003
    - Founded by an internationally renowned group of university professors in the biotech
      cluster of Cologne, Germany
     
  • 2004
    - Invention of the CAP Technology by successful immortalization of  human
      amniocytes
     
  • 2007
    - Completion of entire regulatory data sets and development of CAP- T Technology
     
  • 2008
    - Entrance into European market
     
  • 2010
    - CEVEC opens subsidiary in the USA and enters the Asia / Pacific market
     
  • 2011
    - Closing of 6M € series B financing round
     
  • 2012
    - Closing of 2,8M € series C financing round
    - Several strategic license agreements
    - Several cell line sales agreements
     
  • 2013
    -
    Foundation of a spin-out company, CAP-CMV GmbH focusing  exlusively on the
      clinical development of a novel human CMV vaccine.
    - Completion of first clinical Phase I trial in humans with a CAP-derived
       biotherapeutic
     
  • 2014
    - Launch of CMO services